Type 2 Diabetes Mellitus: Update Bulletin 1 [Report Updated: 01122017] Prices from USD $1095

Gain new key opinion leader KOL insights on the latest events happening in T2DM. Topics covered include; expert views on Novo Nordisk's recently approved onceweekly GLP1 agonist, semaglutide Ozempic; opinions on the results of the Phase IIIb/IV EXSCEL study which is assessing the cardiovascular CV risk of AstraZeneca's Bydureon exenatide extended release in T2DM patients; and views on Zafgen's ZGN1061, a fumagillinclass, injectable small molecule second generation MetAP2 inhibitor, which recently entered Phase II clinical development.

Business Questions:

Do KOLs perceive semaglutide to have any advantages over other onceweekly GLP1 agonists?

What is KOL perception of semaglutide's safety profile?

Where do experts see this semaglutide fitting into the treatment algorithm?

How do KOLs view the results of the EXSCEL study and will it impact prescribing of Bydureon?

Do KOLs raise any new safety concerns based on the findings of the EXSCEL study?

What strategies do experts suggest for growing Bydureon's market share?

How do KOLs perceive ZGN1061's mechanism of action?

How do KOLs view ZGN1061's subcutaneous mode of delivery?

Where do KOLs see ZGN1061 fitting into the T2DM treatment algorithm?

Original Article: Type 2 Diabetes Mellitus: Update Bulletin 1 [Report Updated: 01122017] Prices from USD $1095

More From BioPortfolio on "Type 2 Diabetes Mellitus: Update Bulletin 1 [Report Updated: 01122017] Prices from USD $1095"